Value Sense
SLN
Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
LTM Revenue
$20.6M
YoY Growth
-40.0%
3Y CAGR
+22.7%
5Y CAGR
+165.8%
Stock quality & Intrinsic value
6/10
99.8% overvalued
SLN
is (99.8%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Silence Therapeutics plc Revenue

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
$291.4K
$926.5K
$3,587.3K
$8,100.8K
$4,092.8K
$2,698.5K
$3,657.6K
$1,112.8K
$258.3K
$183.1K
$24.7K
$0.0
$1,044.1K
$20.6K
$0.0
$311.5K
$7,034.0K
$17.1M
$21.7M
$31.6M
SLN
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for SLN and see if it's the right time to invest.
Dive in

Silence Therapeutics plc (SLN) Revenue comparison analysis

General

LTM Revenue

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Silence Therapeutics plc logo
Silence Therapeutics plcSLN
$20.6M
(40.0%)
25.8%
166.0%
Median Peer Set
$3,307.7M
18.9%
16.4%
20.2%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
$42.1B
24.9%
27.3%
18.9%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
$14.2B
8.3%
(4.0%)
12.6%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
$11.0B
11.5%
13.3%
21.5%
Incyte Corporation logo
Incyte CorporationINCY
$4,241.2M
14.8%
12.4%
14.5%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
$3,316.8M
50.5%
46.2%
50.5%
BioNTech SE logo
BioNTech SEBNTX
$3,298.6M
(53.3%)
(39.6%)
83.9%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
$2,877.4M
23.6%
19.5%
14.7%
argenx SE logo
argenx SEARGX
$2,258.9M
127.3%
65.7%
106.9%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
$2,248.2M
23.0%
38.6%
59.2%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
$0.0
N/A
(100.0%)
(100.0%)

SLN key stats

USD
GBP
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.3
0.0%
0.9
217.9%
3.6
287.2%
8.1
125.8%
4.1
(49.5%)
2.7
(34.1%)
3.7
35.5%
1.1
(69.6%)
0.3
(76.8%)
0.2
(29.1%)
0.0
(86.5%)
0.0
(100.0%)
1.0
0.0%
0.0
(98.0%)
0.0
(100.0%)
0.3
0.0%
7.0
2,158.4%
17.1
142.7%
21.7
26.8%
31.6
45.7%
Cost of Goods Sold (COGS)0.00.00.09.712.47.99.05.45.48.814.610.911.810.213.00.04.810.313.512.8
Gross Profit
% margin
0.3
100.0%
0.9
100.0%
3.6
100.0%
(1.6)
(19.7%)
(8.3)
(203.8%)
(5.2)
(194.4%)
(5.3)
(146.0%)
(4.3)
(384.3%)
(5.1)
(1,972.4%)
(8.7)
(4,727.4%)
(14.6)
(59,126.7%)
(10.9)
0.0%
(10.8)
(1,031.3%)
(10.2)
(49,543.8%)
(13.0)
0.0%
0.3
100.0%
2.2
31.3%
6.8
39.9%
8.2
37.8%
18.7
59.3%
Operating Expenses6.58.011.49.76.16.67.94.29.514.420.014.917.218.627.529.348.269.868.380.4
Research & Development Expenses (R&D)3.13.05.99.712.47.99.05.45.48.814.610.911.810.213.017.025.942.344.054.7
Selling, General & Administrative Expenses (SG&A)3.45.05.610.06.15.07.94.24.15.55.44.15.48.314.512.318.027.524.325.7
Operating Income
% margin
(6.2)
(2,118.2%)
(7.1)
(765.8%)
(7.9)
(219.2%)
(11.6)
(143.0%)
(14.4)
(352.7%)
(11.8)
(438.4%)
(13.4)
(365.9%)
(9.3)
(833.7%)
(41.7)
(16,143.6%)
(14.2)
(7,753.8%)
(20.0)
(80,846.7%)
(14.9)
0.0%
(16.1)
(1,546.2%)
(18.5)
(89,943.8%)
(27.5)
0.0%
(29.0)
(9,317.2%)
(46.0)
(654.3%)
(63.0)
(369.0%)
(60.1)
(277.7%)
(61.7)
(195.5%)
Interest Income0.20.50.61.10.70.10.10.10.00.10.20.32.10.30.10.00.20.00.31.8
Interest Expense0.10.00.00.0(0.1)0.00.10.00.00.00.00.00.00.00.00.20.40.00.10.0
Pre-tax Income(6.1)(6.6)(7.3)(10.5)(13.8)(11.8)(13.6)(9.2)(41.7)(14.1)(19.7)(14.4)(14.1)(4.9)(27.4)(29.2)(46.3)(63.1)(58.6)(62.6)
Income Tax
% effective tax rate
(0.6)
10.6%
(0.1)
1.4%
(0.2)
2.9%
(0.3)
2.6%
(0.7)
4.8%
(0.1)
0.5%
0.2
(1.6%)
(0.1)
0.9%
(0.0)
0.1%
(0.1)
0.8%
(1.5)
7.4%
(4.3)
29.5%
(2.6)
18.5%
(2.8)
57.1%
(2.8)
10.3%
(4.2)
14.4%
(4.5)
9.7%
(8.9)
14.1%
(8.5)
14.5%
(8.8)
14.0%
Net Income
% margin
(5.4)
(1,859.1%)
(6.5)
(704.3%)
(7.0)
(196.5%)
(10.2)
(126.2%)
(13.8)
(336.6%)
(11.7)
(433.6%)
(13.6)
(371.7%)
(9.2)
(826.7%)
(41.7)
(16,125.2%)
(14.1)
(7,694.0%)
(18.3)
(73,920.0%)
(10.2)
0.0%
(11.4)
(1,096.1%)
(2.1)
(10,112.5%)
(24.6)
0.0%
(25.0)
(8,025.4%)
(41.8)
(594.0%)
(54.2)
(317.4%)
(50.1)
(231.4%)
(53.8)
(170.5%)
EPS(34.04)(16.07)(11.11)(13.19)(17.23)(13.03)(7.33)(2.95)(6.51)(0.95)(1.09)(0.47)(0.49)(0.09)(1.05)(1.00)(1.53)(1.83)(1.56)(1.45)
Diluted EPS(34.04)(16.07)(11.11)(13.19)(17.23)(13.03)(7.33)(2.95)(6.51)(0.95)(1.09)(0.47)(0.49)(0.09)(1.05)(1.00)(1.53)(1.83)(1.56)(1.45)
EBITDA
% margin
(5.9)
(2,011.3%)
(6.2)
(671.5%)
(6.6)
(184.2%)
(10.6)
(131.4%)
(13.8)
(336.8%)
(11.1)
(413.1%)
(12.6)
(345.3%)
(8.7)
(780.8%)
(8.4)
(3,255.8%)
(13.7)
(7,500.0%)
(19.4)
(78,633.3%)
(14.7)
0.0%
(15.7)
(1,506.0%)
(4.3)
(20,793.8%)
(26.9)
0.0%
(28.5)
(9,161.9%)
(45.6)
(648.5%)
(62.5)
(365.9%)
(59.2)
(273.6%)
(61.9)
(196.2%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Silence Therapeutics plc's Revenue?

As of today, Silence Therapeutics plc's last 12-month Revenue is $20.6M, based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Silence Therapeutics plc's Revenue growth rate?

Over the last year, Silence Therapeutics plc's Revenue growth was (40.0%). The average annual Revenue growth rates for Silence Therapeutics plc have been 48.1% over the past three years, 165.8% over the past five years.

3) Is Silence Therapeutics plc's Revenue growth rate Good?

Over the last year, Silence Therapeutics plc's Revenue growth was (40.0%), which is lower than industry growth of 1.8%. It indicates that Silence Therapeutics plc's Revenue growth is Bad.

4) How does Silence Therapeutics plc's Revenue growth rate compare to its peers?

Over the last year, Silence Therapeutics plc's Revenue growth was (40.0%), which is lower than peer median growth of 9.8%. The list of peers includes NVO, REGN, VRTX, INCY, BGNE, BNTX, UTHR, ARGX, ALNY, SMMT etc.